drugset / Trial / NCT03002935
A Safety Study of Orally Administered BPM31510 in Healthy Subjects
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, Phase I study of the bioavailability and safety of BPM31510 administered orally in healthy subjects dosed 3 times daily for 14 days. The last study dose is administered on Day 15 (one morning dose only). The study will consist of 25 subjects.
Timeline
- Start
- 2017-01
- Primary completion
- 2017-03
- Completion
- 2017-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Coenzyme Q10 | Other / unclassified | 3200 mg | Oral |
Indications
No indication recorded.